Multiple Myeloma

>

Latest News

Data from DREAMM-7 and DREAMM-8 support the marketing authorization application for the belantamab mafodotin combinations in multiple myeloma.
EMA Accepts Application for Belantamab Mafodotin in R/R Multiple Myeloma

July 19th 2024

Data from DREAMM-7 and DREAMM-8 support the marketing authorization application for the belantamab mafodotin combinations in multiple myeloma.

Sequencing Bispecifics and CAR T-Cell Therapy in R/R Multiple Myeloma
Sequencing Bispecifics and CAR T-Cell Therapy in R/R Multiple Myeloma

July 14th 2024

Leveraging CAR T-Cell Therapy Advancements in R/R Multiple Myeloma
Leveraging CAR T-Cell Therapy Advancements in R/R Multiple Myeloma

July 13th 2024

Second interim analysis findings from CARDITUDE-4 show no new safety signals with cilta-cel in relapsed, lenalidomide-refractory multiple myeloma.
Cilta-cel Improves Survival Vs Standard Therapy in R/R Multiple Myeloma

July 3rd 2024

Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials
Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials

June 14th 2024

Video Series
Video Interviews
Podcasts
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.
Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.
Krina Patel, MD, MSc, discusses research and initiatives that may help to mitigate disparities in patients with multiple myeloma including factors such as gender, race, and ethnicity.
Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.

More News